Chidubem A. V. Okeke

Chidubem A. V. Okeke

Auto-generated profile, based on publicly available information

Chidubem A. V. Okeke

From the, Department of Dermatology, Howard University College of Medicine, Washington, District of Columbia, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
COChidubem Av Okeke
Chidubem Av Okeke
RKRamona Khanna
Ramona Khanna
AEAlison Ehrlich
Alison Ehrlich
The recent global pandemic has resulted in increased use of quaternary ammonium compounds (QACs). Currently, QACs are active ingredients in 292 disinfectants recommended by the US EPA for use against SARS-CoV-2. Among QACs, benzalkonium chloride (BAK), cetrimonium bromide (CTAB), cetrimonium chloride (CTAC), didecyldimethylammonium chloride (DDAC), cetrimide, quaternium-15, cetylpyridinium chloride (CPC), and benzethonium chloride (BEC) were all identified as potential culprits of skin sensitivity. Given their widespread utilization, additional research is needed to better classify their dermal effects and identify other cross-reactors. In this review, we aimed to expand our knowledge about these QACs to further dissect its potential allergic and irritant dermal effects on healthcare workers during COVID-19.

9 June 2021 in Dermatology
Verified
Journal Article
Closed access
PDF file
COChidubem A.V. Okeke
Chidubem A.V. Okeke
JPJessica D. Perry
Jessica D. Perry
FSFaith C. Simmonds
Faith C. Simmonds
AEAzure B. Erskine
Azure B. Erskine
WSWilliam D. Shipman
William D. Shipman
ABAngel S. Byrd
Angel S. Byrd
Despite the recent momentum of skin of color conversations in dermatology, adequate research on skin of color diseases is still lacking and African Americans/Blacks are often underrepresented in clinical trials. This underrepresentation is especially glaring in hidradenitis suppurativa (HS) clinical trials [1]. HS is a chronic inflammatory skin condition that commonly affects intertriginous areas and is characterized by painful nodules, draining sinus tracts, and hypertrophic scarring [2]. A recent systematic review focusing on racial populations reports the average prevalence rate of HS as highest in African Americans compared to both Whites and Hispanics/Latinos [3]. Additionally, a study evaluating 47,690 HS patients across the USA found that the disease affects 54.1% (25,780/47,690) Whites compared to 32.6% (15,540/47,690) African Americans; however, when standardized to the US population, the adjusted prevalence of HS was shown to disproportionately affect African American patients with a three-fold increase compared to Whites [4]. Taking into account the wide distribution of populations affected, African Americans are minimally included in HS clinical trials [1]. Of 15 phase II and III HS trials published over the last 12 years (2007–2019), 68% of the participants were Caucasian while only 14.0% were of African descent [1]. This disparity hinders our complete understanding of the therapeutic effects and responses in African Americans, which may lead to the development and use of HS treatments that are neither reflective nor fully applicable to diverse patient populations. The lack of racial and ethnic diversity in HS clinical trials has been highlighted in the literature [1], but barriers and possible explanations are still unclear. Herein we explore the lack of African American representation in these studies by examining the clinical trial locations within the USA and by discussing potential barriers to African American inclusion.

9 July 2020 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
COChidubem A. V. Okeke
Chidubem A. V. Okeke
WSWilliam D. Shipman
William D. Shipman
JPJessica D. Perry
Jessica D. Perry
MKMichelle L. Kerns
Michelle L. Kerns
GOGinette A. Okoye
Ginette A. Okoye
ABAngel S. Byrd
Angel S. Byrd
(2020). Treating hidradenitis suppurativa during the COVID-19 pandemic: teledermatology exams of sensitive body areas. Journal of Dermatological Treatment. Ahead of Print.

21 August 2023 in International Journal of Women's Dermatology
Verified
Journal Article
Open access
COChidubem A. V. Bs Okeke
Chidubem A. V. Bs Okeke
JTJoseph Bs Tran
Joseph Bs Tran
IWIxavion Bs Wright
Ixavion Bs Wright
GOGinette A. Okoye
Ginette A. Okoye
CBCheryl M. Burgess
Cheryl M. Burgess
ABAngel S. Byrd
Angel S. Byrd
Background: Direct-to-consumer advertisements (DTCAs) in medical marketing serve as a prominent modality to deliver information to an increasingly diverse audience of consumers and increase prescription sales. In dermatology, advertisements have the potential to shape the public’s opinions, aid in the understanding of skin conditions, and raise awareness of available treatments. Objective: To investigate and characterize the representation of skin tones in DTCAs. Methods: Nielsen ratings were utilized to identify the networks most watched by Black viewers in 2022. Programming on NBCUniversal, ABC, CBS, and FOX that aired in the District of Columbia, suburban Maryland, and Northern Virginia from June 2022 to July 2022 was reviewed for DTCAs. DTCAs were then analyzed to determine the skin tones of models and skin conditions depicted on models with darkly pigmented skin. Results: Of the 106 DTCAs related to dermatologic conditions, there were 13 unique advertisements featuring 32 unique models. Four advertisements depicted the skin condition on darkly pigmented skin tones. Using the Monk Skin Tone (MST) scale to assess the 32 unique individuals, only 25% (n = 8) were rated at an MST 7 or above, and 6.25% (n = 2) were rated at an MST 10. Limitations: This study has the limitation of only sampling DTCAs from Washington, District of Columbia which does not fully represent all dermatology-related DTCAs in the United States. Conclusion: Results of this content analysis demonstrate that the number of persons of color within dermatologic DTCAs is 23%, whereas there are 13.6% Black individuals in the 2021 US census. This suggests that DTCAs are becoming more diverse since 2018. However, findings also show that the vast majority of DTCAs do not include models with darkly pigmented skin, and there remains a lack of advertisements depicting skin disease among people of color. Given the role of DTCAs in informing and aiding patients’ requests for prescription drugs, representation of all skin tones is essential for this communication to be effective, especially in the field of dermatology.

23 August 2023 in Journal of Dermatology & Cosmetology
Verified
Journal Article
Open access
PDF file
COChidubem Av Okeke
Chidubem Av Okeke
JWJonathan P Williams
Jonathan P Williams
JTJoseph H Tran
Joseph H Tran
ABAngel S Byrd
Angel S Byrd
Background: Ongoing investigations established the relationship between adverse childhood experiences (ACEs) and chronic diseases, such as high blood pressure, diabetes, atopic dermatitis, and psoriasis. However, the specific association between ACEs and skin cancer remains relatively unexplored in scientific literature. Objective: This study aimed to evaluate the relationship between adverse childhood experiences (ACEs) and measures of health-related quality of life (HRQOL) among individuals with a skin cancer diagnosis. Methods: Data from the 2019 Behavioral Risk Factors and Surveillance Study (BRFSS) were analyzed. The study included 418,268 adults, with 41,773 individuals diagnosed with skin cancer. HRQOL measures, including physical health, mental health, and lifestyle impairment, were assessed using self-reported data. ACEs were identified through participants' responses to 11 specific questions. Multivariable logistic regression analyses adjusted for demographic variables. Results: Skin cancer survivors with a history of ACEs reported significantly poorer physical health (OR 1.39, 95% CI 1.24-1.56) and mental health (OR 2.13, 95% CI 1.81-2.51) compared to those without ACEs. They also experienced higher levels of lifestyle impairment related to health (OR 1.31, 95% CI 1.16-1.48). Commonly reported ACEs included parental separation, exposure to domestic violence, and verbal abuse. Discussion: This study highlights the detrimental impact of childhood maltreatment on HRQOL among skin cancer survivors. Healthcare professionals should be attentive to the unique needs of this population by providing comprehensive support and interventions. Conclusion: Childhood maltreatment has a significant negative impact on HRQOL among skin cancer survivors. The study emphasizes the importance of addressing the psychological and emotional well-being of individuals with a history of ACEs. Healthcare professionals should consider the specific needs of this vulnerable population to provide appropriate care and support. Further research is required to deepen our understanding of the underlying mechanisms and to develop effective interventions to improve the well-being of skin cancer survivors with a history of childhood maltreatment. Furthermore, longitudinal analyses and objective measures are needed to establish causal relationships and mitigate potential biases.

19 February 2025 in Dermatitis®
Verified
Journal Article
Closed access
COChidubem A. V. Okeke
Chidubem A. V. Okeke
MPMatthew Ponzini
Matthew Ponzini
SSSydney D. Sullivan
Sydney D. Sullivan
LHLauren W. Hastings
Lauren W. Hastings
OKOlivia Keller
Olivia Keller
PWPeggy A. Wu
Peggy A. Wu
In this study, we assessed the demographics of patients diagnosed with dermatitis in internal medicine, dermatology, or family medicine in the University of California, Davis hospital system. Characteristics between the specialties were compared using logistic regression in R®. We found that underrepresented racial and ethnic groups are more likely to be diagnosed with dermatitis by a non-dermatologist and that MediCal and Medicare beneficiaries were more likely to be seen by dermatology than internal medicine or family medicine for dermatitis. Additional studies should explore the causality of the associations noted in this investigation.